Champions Oncology, Inc. (CSBR) News
Filter CSBR News Items
CSBR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CSBR News Highlights
- For CSBR, its 30 day story count is now at 2.
- Over the past 2 days, the trend for CSBR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CSBR are NOTE.
Latest CSBR News From Around the Web
Below are the latest news stories about CHAMPIONS ONCOLOGY INC that investors may wish to consider to help them evaluate CSBR as an investment opportunity.
Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2024 Earnings Call TranscriptChampions Oncology, Inc. (NASDAQ:CSBR) Q2 2024 Earnings Call Transcript December 12, 2023 Champions Oncology, Inc. beats earnings expectations. Reported EPS is $-0.15, expectations were $-0.17. Operator: Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2024 Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please note, this conference […] |
CSBR Stock Earnings: Champions Oncology Beats EPS, Misses Revenue for Q2 2024CSBR stock results show that Champions Oncology beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. |
Champions Oncology Reports Quarterly Revenue of $11.6 MillionHACKENSACK, NJ / ACCESSWIRE / December 12, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second ... |
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023HACKENSACK, NJ / ACCESSWIRE / December 4, 2023 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second ... |
The past three years for Champions Oncology (NASDAQ:CSBR) investors has not been profitableThe truth is that if you invest for long enough, you're going to end up with some losing stocks. Long term Champions... |
Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS CertificationHACKENSACK, NJ / ACCESSWIRE / November 2, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced its European research operations site in Bresso, ... |
Champions Oncology Announces the Addition of Brady Davis as PresidentHACKENSACK, NJ / ACCESSWIRE / October 17, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has appointed Brady Davis as President to continue to ... |
Favourable Signals For Champions Oncology: Numerous Insiders Acquired StockWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Champions Oncology Independent Director Acquires 14% More StockEven if it's not a huge purchase, we think it was good to see that Daniel Mendelson, the Independent Director of... |
Champions Oncology Reports Quarterly Revenue of $12.6 MillionChampions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2024, ended July 31, 2023. |